- Affirmative Recovery
- Alternative Dispute Resolution
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Childhood Sexual Abuse Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Wealth Planning, Administration, and Disputes
-
August 6, 2020Hollis Salzman Named to Benchmark Litigation's Top 250 Women in Litigation List
-
July 31, 2020Patrick Arenz and Aaron Fahrenkrog named to Benchmark Litigation 40 & Under Hot List
-
July 27, 2020Christine Yun Sauer Shortlisted for Chambers Diversity and Inclusion Awards
-
August 11, 2020Century City Bar Association Distinguished Speaker Series
-
August 12, 13, 19 and 20, 2020Minnesota Association for Justice (MAJ) 38th Annual Meeting and Virtual Convention
-
August 14, 2020Notable Recent & Pending Class Action Cases in the 9th Circuit and SCOTUS
-
August 3, 2020Request for Amici: Tell SCOTUS to Incentivize Original Fictional Characters through Copyright
-
Summer 2020ANDA Approvals
-
Summer 2020ANDA Litigation Settlements
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Investment Decisions for Investors and Entrepreneurs Considering 505(b)(2) Drug Applications
How to Make Sure Your Train Is on the Fast Track
April 19, 2017
Webinar
Related Professionals
Are you an investor or entrepreneur considering 505(b)(2) drug applications? Join Jake Holdreith, Robins Kaplan, and Ken Phelps, Camargo Pharmaceutical Services for a complimentary webinar. Jake and Ken will discuss in detail the topics listed below:
- Does your new drug application support your legal strategy?
- When is it likely that the FDA will treat product as a drug/device combination?
- What do the FDA’s pre-submission comments really mean for your application?
- How can you predict when the FDA will ask to identify the reference listed drug in a literature based 505(b)(2) filing?
This complimentary webinar will be followed with a Q & A session.
Related Publications
April 2, 2020
Remote Depositions in the Era of COVID-19
Ian Millican
September 26, 2018
February 10, 2015
July 15, 2013
Aventis Pharma., Inc. v. Amino Chemicals Ltd.
GENERICally Speaking Summer 2013
Related News
March 21, 2011
January 25, 2008
Mylan Hit With $69.2M In Treble Damages
Competition Law360
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.